Unveiling Lactylation: A Novel Frontier in Cancer Stemness and Therapy
Advanced Science · 2026-08 · 13 (46)
DOI: 10.1002/advs.202521985 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 23.07.2026. Verfasst von Ting Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau SAR, China. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Neoplasms, Protein Processing, Post-Translational. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Science and Technology Major Project for Prevention and Treatment of Cancer, Cardio-Cerebrovascular, Respiratory and Metabolic Diseases, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer stemness represents a dynamic cellular state endowed with tumor‐initiating capacity, self‐renewal potential, and differentiation plasticity, functioning as a key driver of tumor recurrence, metastasis, and therapy resistance. Tumor metabolism and epigenetic regulation are two fundamental mechanisms that modulate cancer stemness. Lactylation, a novel post‐translational modification, has emerged as a pivotal bridge linking these two processes. Accumulating evidence highlights elevated lactylation as a critical driver of cancer stemness. To elucidate the underlying mechanisms, we systematically evaluate how lactylation orchestrates the cancer stem cell (CSC) landscape across four functional dimensions: self‐renewal maintenance, stemness‐associated signaling activation, microenvironmental adaptation, and lineage plasticity induction. Furthermore, we summarize the dynamic regulatory network governing this modification, comprising both key enzymes and indirect modulators. Beyond highlighting promising therapeutic targets and preclinical successes, we critically assess the significant challenges hindering clinical translation. This framework provides a roadmap for targeting the metabolic‐epigenetic circuitry of CSCs to combat therapy resistance and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau SAR, China.
- Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Yu-Yue Pathology Scientific Research Center, Chongqing, China.
- Jinfeng Laboratory, Chongqing, China.
- Collaborative Innovation Centre of Regenerative Medicine and Medical Bioresource Development and Application Co-Constructed By the Province and Ministry, Guangxi Medical University, Nanning, China.
ORCID-Profile: Chuan Xu
Förderung
- National Key Research and Development Program of China
- National Science and Technology Major Project for Prevention and Treatment of Cancer, Cardio-Cerebrovascular, Respiratory and Metabolic Diseases
- National Natural Science Foundation of China
- Sichuan Province Natural Science Foundation Key Project
- Major Project of Chongqing Natural Science Foundation
Zitieren
APA
Li, T., Gu, H., Liu, C., Lv, Y., Li, F., Liang, L., Yi, J., Wang, X., Zhu, Y. Z., & Xu, C. (2026). Unveiling Lactylation: A Novel Frontier in Cancer Stemness and Therapy. Advanced Science, 13(46). https://doi.org/10.1002/advs.202521985
Vancouver
Li T, Gu H, Liu C, Lv Y, Li F, Liang L, et al. Unveiling Lactylation: A Novel Frontier in Cancer Stemness and Therapy. Advanced Science. 2026;13(46). doi:10.1002/advs.202521985
BibTeX
@article{Li2026,
author = {Li, Ting and Gu, Hongyu and Liu, Chang and Lv, Yuesheng and Li, Feifei and Liang, Liang and Yi, Jia and Wang, Xuanyi and Zhu, Yi Zhun and Xu, Chuan},
title = {Unveiling Lactylation: A Novel Frontier in Cancer Stemness and Therapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {46},
doi = {10.1002/advs.202521985}
}
EUVIMED